2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2440

Bone Mineral Density in Psoriatic Arthritis: Results from a Longitudinal Study
Abstract Number: 2216

Bone Mineral Density of the Spine, Hip, and Distal Radius in Patients with Postmenopausal Osteoporosis
Abstract Number: 1896

Breastfeeding in Women with Rheumatic Diseases
Abstract Number: PP03

Bridging the Gap: Leveraging Social Media to Improve Patient Support; Build a Path to Collaborative Medicine
Abstract Number: 1996

Bromodomain Inhibitor, I-BET762 Inhibits Production of Pro-inflammatory in Rheumatoid Arthritis Fibroblast-like Synoviocytes and Differentiation of Osteoclast
Abstract Number: 1627

Bronchoalveolar Lavage Fluid Analysis and Mortality Risk in Systemic Lupus Erythematosus Patients with Pneumonia and Respiratory Failure
Abstract Number: 974

Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Disease: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
Abstract Number: 967

Bruton’s Tyrosine Kinase (BTK) Pathway Is Active in Synovium at Various Stages of Rheumatoid Arthritis Disease Progression
Abstract Number: 1903

BTK Overexpression Is Associated with the Risk of Lymphoma in Primary Sjögren’s Syndrome: Data from Whole Blood Transcriptome of 346 Patients Followed-up Prospectively for 10 Years
Abstract Number: 2477

Burden of Disease at Treatment Initiation Among Biologic-Naïve Patients with Oligoarticular versus Polyarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Abstract Number: 2295

Burden of Systemic Lupus Erythematosus Among Korean Women in Childbearing Years Based on the National Health Insurance Service Data
Abstract Number: 1008

C-X-C Motif Chemokine 10 (CXCL10) as a Transcriptomic Biomarker of Psoriatic Arthritis Susceptibility
Abstract Number: 1567

Cachexia in Systemic Lupus Erythematosus
Abstract Number: 364

Calcium Pyrophosphate Crystal Arthritis During Hospitalizations: A Prospective, Crystal-Proven Case Series
Abstract Number: 2820

Calcium/ Calmodulin – Dependent Protein Kinase IV Associates with Phosphofructokinase to Promote Glycolysis and Limit IL-2 Production

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].